New SuperSonic MACH 20 Ultrasound System Is Designed to Optimize Costs While Improving Outcomes

January 28, 2021

SuperSonic MACH 20 ultrasound system by Hologic has been added to the company’s portfolio. Hologic now offers three tiers of ultrasound technology, ensuring more facilities have access to customized ultrasound solutions to address their unique imaging needs.

Each of the systems is designed to increase efficiency and diagnostic accuracy, features exceptional image quality and innovative imaging modes, and offers an intuitive user experience.

As the leader in breast imaging, we strive daily to deliver superior health care solutions that meet the unique and ever-changing needs of our customers,” said Jennifer Meade, Hologic’s Division President, Breast and Skeletal Health Solutions. “By continuing to heavily invest in our growing ultrasound portfolio, we’re delivering on that promise. In less than a year, we’ve brought two new ultrasound systems to market through accelerated innovation, providing our customers with an array of targeted solutions designed to optimize ultrasound imaging and enhance the patient experience.”

The latest addition to Hologic’s ultrasound portfolio, the SuperSonic MACH 20 ultrasound system, provides added clinical value for general and specialty ultrasound imaging, including of the breast, liver, muscles, and tendons. It features excellent B-mode image quality and runs on the same UltraFast™ imaging technology that powers Hologic’s full line of SuperSonic ultrasound systems, allowing users to perform dynamic tissue stiffness evaluation with ShearWave™ PLUS elastography. Radiologists and sonographers also enjoy an intuitive, ergonomic user experience thanks to the SonicPad™ touchpad, which is designed to reduce examination time and operator fatigue and injury.

Hologic has been expanding its comprehensive portfolio of ultrasound solutions since its acquisition of SuperSonic Imagine®, a pioneer in the field of ultrasound imaging.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version